Being diagnosed with Myelodysplastic Syndrome (MDS) can feel overwhelming, especially when you are navigating complex treatment decisions in your home country. MDS is a bone marrow disorder in which the body does not produce healthy blood cells effectively, leading to anemia, infections, or bleeding complications. In some patients, MDS can progress to Acute Myeloid Leukemia, making timely and appropriate treatment critical.
For many international patients, the challenges go beyond medical concerns. Questions about treatment quality, cost, waiting times, transplant eligibility, donor matching, and travel logistics often add to the stress.
India has emerged as a leading global destination for advanced hematology care and bone marrow transplantation. With internationally trained specialists, state-of-the-art transplant units, and significantly lower treatment costs compared to Western countries, India offers a strong balance of quality and affordability.
This comprehensive guide will help you understand:
- How MDS is diagnosed and risk-graded
- Treatment options available in India, including stem cell transplant
- Estimated treatment costs
- Expected outcomes and survival rates
- Medical visa and travel planning
- How to prepare for treatment and post-transplant recovery
At Hospidio, our goal is to simplify this journey for international patients, connecting you with leading hematologists in India while coordinating travel, hospital admission, documentation, and recovery planning.
We Handle the Planning
You Focus on Recovery
From Medical Visa assistance to airport pick-up and local stay, HOSPIDIO manages your entire medical trip.
Send Your Treatment Request
What is Myelodysplastic Syndrome (MDS)?
Myelodysplastic Syndrome (MDS) is a disorder of the bone marrow - the spongy tissue inside bones responsible for producing blood cells.
In MDS, the bone marrow produces abnormal, immature blood cells that do not function properly. As a result, patients may develop:
- Anemia (low red blood cells), leading to fatigue, weakness, shortness of breath
- Low white blood cells, leading to frequent or severe infections
- Low platelets causing easy bruising or bleeding
Over time, the bone marrow becomes less effective at producing healthy blood cells, which can significantly impact daily life.
Is MDS a Cancer?
MDS is often classified under blood cancers because it involves abnormal cell growth in the bone marrow. It is also sometimes described as a bone marrow failure disorder.
In some patients, MDS can progress to Acute Myeloid Leukemia (AML), a more aggressive form of blood cancer. However, not all MDS cases transform into leukemia. The risk depends on the subtype and risk category of the disease.
This is why accurate diagnosis and proper risk assessment are essential before deciding on treatment.
Can MDS be cured?
The only potentially curative treatment for MDS is an allogeneic stem cell (bone marrow) transplant.
During this procedure:
- Diseased bone marrow is replaced
- Healthy stem cells from a compatible donor are infused
- The new cells rebuild a healthy blood-forming system
However, not all patients are eligible for transplant. Factors such as age, overall health, risk category of MDS, and donor availability play a major role in determining eligibility.
For patients who are not transplant candidates, other treatments can help control the disease, reduce symptoms, and improve quality of life.
Common Symptoms MDS Patients Notice First
Many patients with myelodysplastic syndrome are diagnosed after experiencing persistent symptoms that do not improve with routine treatment. Because MDS affects blood cell production, the symptoms are usually related to low blood counts.
Fatigue and Weakness (Low Red Blood Cells - Anemia)
Anemia is one of the earliest and most common signs of MDS. Patients may experience:
- Constant tiredness despite adequate rest
- Shortness of breath with mild activity
- Dizziness or lightheadedness
- Pale skin
Some patients initially assume this is due to stress, aging, or nutritional deficiency before blood tests reveal an underlying bone marrow disorder.
Frequent or Severe Infections (Low White Blood Cells)
White blood cells help the body fight infections. When levels are low, patients may notice:
- Repeated respiratory infections
- Slow recovery from common illnesses
- Unexplained fevers
- Mouth ulcers or gum infections
Easy Bruising or Bleeding (Low Platelets)
Platelets are responsible for blood clotting. When platelet counts drop, patients may develop:
- Frequent nosebleed
- Bleeding gums
- Prolonged bleeding from small cuts
- Unexplained bruises
- Tiny red or purple spots on the skin (petechiae)
These symptoms should never be ignored, especially if they appear suddenly or worsen over time.
When to Seek Urgent Medical Care
Patients with suspected or diagnosed MDS should seek immediate medical attention if they experience:
- Fever (especially above 38°C / 100.4°F)
- Uncontrolled bleeding
- Severe shortness of breath
- Chest pain
- Extreme weakness or fainting
Low white blood cell counts can make even minor infections potentially serious. Early intervention can be life saving.
For international patients considering MDS treatment abroad, recognizing these warning signs is critical. Stabilizing blood counts and managing urgent complications is often the first step before planning advanced treatment such as stem cell transplant.
Diagnosis and Staging for MDS: What Tests You’ll Need in India
Accurate diagnosis and risk assessment are the foundation of successful MDS treatment. In leading tertiary hospitals in India, most essential tests are completed within 1 to 3 days, allowing doctors to quickly develop a personalized treatment plan.
Core Diagnostic Tests
Complete Blood Count (CBC) + Peripheral Smear
This is usually the first test that raises suspicion of MDS. It measures:
- Red blood cells (for anemia)
- White blood cells (infection risk)
- Platelets (bleeding risk)
A peripheral smear allows doctors to examine the shape and maturity of blood cells under a microscope.
Bone Marrow Aspiration and Biopsy
This is the most important diagnostic test for MDS. A small sample of bone marrow (usually from hip bone) is collected and examined to:
- Assess marrow cellularity
- Identify abnormal or immature cells (blasts)
- Confirm MDS subtype
The procedure is typically done under local anesthesia and takes about 20-30 minutes.
Flow Cytometry (if needed)
Flow cytometry helps identify abnormal cell markers and may assist in distinguishing MDS from other blood disorders.
Cytogenetics and Molecular Testing
These advanced tests are critical for prognosis and treatment planning.
- Cytogenetics (Karyotype/FISH): Detects chromosomal abnormalities
- Molecular Testing (NGS panels): Identifies gene mutations that influence disease behavior and therapy response
Certain genetic abnormalities can indicate a higher risk of progression to AML and may guide decisions about early stem cell transplant.
B) Risk Stratification: Why It Changes Treatment
Not all MDS cases behave the same. Some progress slowly over years, while others advance more aggressively.
Doctors use the Revised International Prognostic Scoring System (IPSS-R) to classify patients into five risk groups:
- Very Low
- Low
- Intermediate
- High
- Very High
In practical terms, patients are often grouped into lower risk MDS and higher risk MDS.
What Doctors Consider Beyond the Score
While IPSS-R is essential, treatment decisions are not based on numbers alone. Indian hematology specialists also evaluate:
- Patient’s age
- Overall health and comorbidities (heart, liver, kidney function)
- Frequency of blood transfusions
- Genetic mutation profile
- Performance status (ability to tolerate intensive therapy)
- Donor availability (if transplant is being considered)
For example: A younger, fit patient with high-risk MDS may be advised early stem cell transplant. An older patient with lower-risk disease may benefit from supportive or targeted drug therapy.
Top Hematologists For MDS Treatment in India
MDS Treatment Goals: Setting the Right Expectations
Treatment for Myelodysplastic Syndrome (MDS) is highly individualized. The goals depend largely on the patient’s risk category, overall health, age, and symptoms. Doctors typically divide treatment objectives into two broad groups: lower-risk MDS and higher-risk MDS.
Understanding these goals early helps patients and families make informed decisions about therapy, travel planning, and long-term care.
Treatment Goals for Lower Risk MDS
For patients with lower-risk disease, the main focus is on managing symptoms and improving quality of life. Many individuals in this category live with MDS for several years with appropriate supportive treatment.
Key treatment goals include:
- Improving blood counts to reduce symptoms such as fatigue or infections
- Reducing the need for frequent blood transfusions
- Preventing complications related to low blood cells
- Maintaining daily functioning and quality of life
Treatments may involve supportive care, growth factor therapies, and disease-modifying medications depending on the patient’s condition.
Treatment Goals for Higher Risk MDS
Higher-risk MDS behaves more aggressively and carries a greater likelihood of progressing to AML. In these cases, treatment focuses on controlling the disease and improving long-term survival.
Doctors usually aim to:
- Slow or delay progression to leukemia
- Extend survival through disease-modifying therapies
- Stabilize blood counts and reduce complications
- Evaluate eligibility for bone marrow transplantation
For eligible patients, allogeneic bone marrow or stem cell transplant remains the only potentially curative treatment option and may be recommended earlier in the treatment course.
MDS Treatments Options Available in India
Treatment for Myelodysplastic Syndrome (MDS) depends on the risk category, symptoms, age, overall health, and genetic profile of the disease. In India, leading hematology centers offer a full spectrum of therapies, from supportive care to advanced stem cell transplantation. The categories below can help international patients understand where they may fit, though the final treatment plan should always be confirmed by a hematology specialist.
Supportive Care (Common for Many Patients)
Supportive care is an essential component of MDS management and is used across both lower risk and higher risk disease to manage symptoms and complications.
Common supportive treatments include:
Red blood cell (RBC) and platelet transfusions
These help correct anemia and reduce bleeding risk when blood counts are very low.
Antibiotics and infection management
Because MDS can weaken the immune system, doctors may prescribe antibiotics promptly when infection occurs.
Growth factor therapy
Medications that stimulate bone marrow to produce more blood cells may be recommended in selected patients.
Infection prevention strategies
Doctors often advise precautions such as vaccination updates, hygiene measures, and early medical evaluation for fever.
Medicines for Lower Risk MDS
Patients with lower risk diseases often receive treatments aimed at improving blood counts and reducing the need for transfusions.
Erythropoiesis- Stimulating Agents (ESAs)
These medications stimulate the bone marrow to produce more red blood cells and may help reduce anemia in selected patients. They are typically considered when hemoglobin levels are low or transfusion needs are increasing.
Lenalidomide for del(5q) MDS
For patients with a specific chromosomal abnormality known as del(5q), treatment with Lenalidomide can significantly reduce transfusion dependence and improve blood counts.
Because this therapy works best in a specific genetic subtype, cytogenetic testing is essential before starting treatment.
Iron Chelation Therapy
Patients who require frequent transfusions may accumulate excess iron in the body, which can affect organs such as the heart and liver.
Iron chelation therapy may be considered when:
- Patients receive regular long-term transfusions
- Iron levels become elevated
- Life expectancy and clinical status suggest long-term benefit
This therapy helps remove excess iron and reduce long-term complications.
Disease Modifying Therapy (Common in Higher Risk MDS)
For patients with higher-risk disease, doctors often use medications designed to slow disease progression and improve survival.
The most widely used therapies are hypomethylating agents, including azacitidine and decitabine. These medications help restore more normal bone marrow function and may delay progression to AML.
Treatment is usually given in cycles over several months, with regular monitoring of blood counts and response.
Immunosuppressive Therapy (Selected Patients)
In certain patients, particularly younger individuals with specific bone marrow features, immunosuppressive therapy may be considered.
This approach works by reducing immune system activity that may be suppressing normal bone marrow function.
Because the benefit varies widely between patients, this treatment decision is highly specialist-driven and requires careful evaluation by an experienced hematologist.
Curative Intent Option: Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
The only treatment that offers a potential cure for MDS is an allogeneic hematopoietic stem cell transplant (HSCT).
During this procedure:
- Diseased bone marrow is replaced
- Healthy stem cells from a donor are infused
- The new cells rebuild the patient’s blood-forming system
Types of Donors for HSCT for MDS
Possible donor sources include:
- Matched sibling donor
- Matched unrelated donor (from international registries)
- Haploidentical donor (half-matched, often a parent or child)
Advances in transplant techniques have significantly expanded donor availability.
When is a Bone Marrow Transplant Recommended For MDS
Doctors usually consider stem cell transplant when:
- The patient has higher-risk MDS
- The disease is likely to progress without intensive treatment
- The patient is fit enough to tolerate the procedure
A suitable donor is availableFor eligible patients, transplant may offer the best chance of long-term remission or cure.
Eligibility: Who Is a Candidate for Which Treatment?
One of the most important questions international patients ask is : “Which treatment option am I likely to qualify for?”
Eligibility for different MDS therapies depends on several factors, including disease risk category, overall health, genetic profile, and transplant fitness. A hematology specialist will review these details before recommending the most appropriate treatment plan.
Below is a simplified guide to help patients understand how doctors typically approach treatment decisions.
A) You May Be Considered for Supportive or Medical Therapy If:
Patients with lower-risk disease or those who may not be immediate candidates for transplant often begin with supportive or disease-controlling therapies.
Doctors may recommend this approach when:
- The disease is classified as lower-risk MDS
- The patient has significant comorbidities (such as heart, lung, or kidney disease)
- Age or overall health makes intensive treatment risky
The disease is relatively stable
- The main goals of this approach are to:
- Reduce dependence on blood transfusions
- Improve blood counts
- Control symptoms such as fatigue or infections
- Maintain quality of life
Treatments may include supportive care, growth factor therapy, or medications such as Lenalidomide or hypomethylating agents depending on the patient’s specific disease features.
B) You May Be Considered for Stem Cell Transplant (HSCT) If:
Doctors may recommend allogeneic hematopoietic stem cell transplant (HSCT) when the potential benefits outweigh the risks.
Patients are usually evaluated for transplant if they have:
- Higher-risk MDS
- A significant chance of progression to AML
- Adequate physical fitness to tolerate intensive treatment
- A suitable stem cell donor
Before proceeding, hospitals perform a detailed transplant fitness evaluation, which may include:
- Heart and lung function tests
- Liver and kidney function tests
- Infection screening
- Performance status assessment
If these criteria are met and a donor is available, transplant may offer the best chance for long-term remission or cure.
C) Why Genetics Matters in MDS Treatment
Genetic mutations detected during molecular testing play a critical role in treatment planning.
Some mutations are associated with more aggressive disease behavior or lower response to therapy. For example, mutations in the TP53 gene are often linked with poorer outcomes, even after transplant.
When such high-risk mutations are present, doctors may:
- Adjust the treatment strategy
- Recommend earlier transplant
- Consider clinical trials or combination therapies
These decisions are highly individualized and require careful discussion between the patient and the treating hematology team.
Cost of MDS Treatment in India (for international patients)
| Treatment / Service | Description | Typical Cost Range (USD) |
| Diagnostic Workup & Bone Marrow Testing | Comprehensive diagnostic evaluation performed at specialized hematology centers. Includes CBC blood tests, peripheral smear, bone marrow aspiration and biopsy, cytogenetic testing, and molecular testing such as NGS panels to determine disease subtype and prognosis. | $1,200 to $2,000 |
| Drug Therapy (Hypomethylating Agents – e.g., Azacitidine) | Disease-modifying therapy commonly used for higher-risk MDS patients. These medications are administered in monthly treatment cycles, and several cycles are typically required before evaluating response. Treatment may be provided in outpatient or inpatient settings. | $1,400 to $3,600 per cycle |
| Blood Transfusion – Red Blood Cells | Used to manage anemia in MDS patients. The cost varies depending on the hospital, city, and supportive monitoring required. | $100 to $180 per unit |
| Blood Transfusion – Platelets | Platelet transfusions help manage low platelet counts and reduce bleeding risks in MDS patients. Additional hospital monitoring may affect the overall cost. | $120 to $240 per unit |
| Allogeneic Stem Cell Transplant (HSCT) | The only potentially curative treatment for MDS. This procedure replaces diseased bone marrow with healthy donor stem cells. Cost varies depending on donor type, conditioning therapy, hospital stay duration, and post-transplant medications and monitoring. | $16,000 to $22,000 |
Note: Actual costs may vary depending on hospital choice, donor availability, treatment complexity, and the patient's medical condition. Through Hospidio, international patients can receive a personalized hospital-wise treatment estimate based on their medical reports and donor plan.
Additional Costs International Patients Should Plan For
| Cost Head | What it Includes | Planning Tip |
| International Flights | Patient + attendant | Keep flexible return dates (treatment timelines vary) |
| Medical Visa + Fees | Patient + medical attendant visa | Apply after hospital invitation letter is ready |
| Accommodation (Pre/Post Treatment) | Hotel or service apartment near hospital | Prefer kitchen + hygiene-friendly stays during low immunity |
| Local Transport | Airport pickup and daily hospital visits | Choose accommodation with short travel time to reduce infection exposure |
| Food & Daily Living | Meals, water, and basic daily needs | Plan for neutropenic diet if advised |
| Repeat OPD Visits + Labs | CBC tests, cultures, and ongoing monitoring | Build buffer for extra tests during fever or infection episodes |
| Donor Logistics (if HSCT) | HLA typing, donor evaluation, stem cell collection | Ask hospitals if donor workup is included in the transplant package |
| Medicines After Discharge | Antibiotics, antivirals, and supportive medicines | HSCT patients may require longer post-discharge medication support |
| Emergency Buffer | Unplanned ICU care or extended hospital stay | Keep contingency funds and clarify insurance coverage |
Success Rate and Outcomes: Setting Realistic Expectations
When considering treatment for Myelodysplastic Syndrome (MDS), many patients want to understand the expected success rates. However, outcomes can vary significantly depending on the type of treatment, the patient’s overall health, and the biological characteristics of the disease. In MDS, “success” may mean different things for different patients, especially when comparing medical therapy with stem cell transplant.
What “Success” Means in MDS Treatment
For Medical Therapy
For many patients, particularly those with lower-risk MDS, the goal is to control the disease and improve quality of life rather than cure it.
Treatment success with medical therapy may include:
- Reduced need for blood transfusions
- Achieving transfusion independence in some patients
- Improved blood counts (red cells, white cells, or platelets)
- Relief from symptoms such as fatigue or frequent infections
- Slower progression of the disease
Medications such as hypomethylating agents (e.g., Azacitidine) are commonly used to stabilize the condition and delay progression to AML.
For Stem Cell Transplant (HSCT)
For eligible patients, allogeneic hematopoietic stem cell transplant (HSCT) is the only treatment with curative potential. In this context, treatment success generally means:
- Long-term remission
- Prevention of disease relapse
- Restoration of healthy bone marrow function
However, transplant is a complex procedure and may involve risks such as infections, graft-versus-host disease (GVHD), or relapse, which is why doctors carefully evaluate whether the benefits outweigh the potential complications.
Outcomes After Stem Cell Transplant
Clinical studies report approximately 40 to 70 percent two-year overall survival after stem cell transplant for MDS patients. Outcomes vary based on several important factors, including:
- Patient age and overall health
- MDS risk category
- Donor type (matched sibling, unrelated donor, or haploidentical donor)
- Conditioning regimen used before transplant
- Genetic mutations present in the disease
Outcomes are generally better when the disease is well controlled before transplant, a closely matched donor is available, and the patient has fewer high-risk genetic mutations. Certain mutations, such as TP53, may be associated with more aggressive disease and a higher risk of relapse.
While survival statistics provide general guidance, individual results can vary significantly. Patients considering treatment in India through Hospidio are encouraged to request center-specific outcomes for patients with similar risk profiles, which can help them make more informed treatment decisions.
Got More Questions? Request A Consultation With a Hematologist.
How Long Do International Patients Need To Stay in India for MDS Treatment?
| Treatment Stage | What Happens During This Stage | Typical Stay Duration in India |
| Screening & Diagnostic Evaluation | Initial medical assessment and confirmation of MDS diagnosis at a hematology center. Doctors typically perform:
| 5 – 10 days |
| Drug Therapy Cycles | Patients receiving medical therapy such as hypomethylating agents (e.g., Azacitidine) typically undergo treatment in monthly cycles.
| Varies by treatment plan First cycle: ~3–4 weeks (may vary) |
| Stem Cell Transplant (HSCT) | Allogeneic hematopoietic stem cell transplant requires intensive treatment and monitoring. The process generally includes:
| 8 – 12 weeks (depending on recovery and complications) |
Note: The exact duration of stay may vary depending on the patient’s condition, treatment response, and transplant plan. Through Hospidio, international patients receive assistance with treatment scheduling, accommodation near the hospital, and follow-up planning to help manage their stay in India more smoothly.
Medical Visa Support for International Patients Looking for MDS Treatment in India
International patients traveling to India for Myelodysplastic Syndrome (MDS) treatment must obtain an Indian Medical Visa before arrival. India has a dedicated visa system for patients seeking specialized care. With guidance from Hospidio and the treating hospital, the process is usually straightforward once the required documents are prepared.
A) Which Visa Category Is Used?
Patients typically apply for an Indian Medical Visa, which allows foreign nationals to travel to India for treatment at recognized hospitals.
Usually, the following visas are issued:
- Medical Visa – for the patient
- Medical Attendant Visa – for a caregiver or accompanying family member
Most embassies allow one or two attendants, depending on the patient’s medical needs and embassy regulations.
B) Common Documents Checklist
Although requirements may vary slightly by country, most patients need:
- Valid passport with sufficient validity
- Recent passport-size photographs
- Completed online visa application form
- Hospital invitation / visa letter confirming treatment
- Medical records and doctor’s reports
- Proof of financial ability to cover treatment and travel
The hospital invitation letter is a key document and is usually provided by the treating hospital.
C) FRRO Registration for Longer Stays
- Patients staying in India for extended treatment periods may need to register with the Foreigners Regional Registration Office (FRRO).
- If the visa validity exceeds 180 days, registration is usually required within 14 days of arrival.
- Hospitals and medical travel coordinators such as Hospidio often assist patients with documentation and appointment guidance for FRRO registration.
Completing visa formalities in advance helps patients focus on treatment and recovery without administrative delays during their stay in India.
Next Steps: How to Plan your MDS Screening and Treatment with HOSPIDIO
If you or a loved one has been diagnosed with Myelodysplastic Syndrome (MDS), planning the next step can feel overwhelming, especially when considering treatment abroad. A structured process helps ensure that medical decisions are made carefully and that travel arrangements are organized efficiently.
Through Hospidio, international patients can follow a step-by-step pathway to evaluate treatment options in India.
1. Share Your Medical Reports
The first step is to submit relevant medical records for preliminary review. These may include:
- Recent complete blood count (CBC) trends
- Bone marrow aspiration or biopsy reports (if already performed)
- History of blood transfusions
- Any previous infection history or hospitalizations
- Prior treatment records, if applicable
These documents help specialists understand the current stage of the disease.
2. Specialist Review and Risk Assessment
Once reports are received, they can be reviewed by an experienced hematologist. The specialist typically evaluates the disease using tools such as the Revised International Prognostic Scoring System to determine the risk category.
This helps guide decisions about whether the patient may benefit from:
- Supportive or medical therapy
- Disease-modifying treatment
- Evaluation for stem cell transplant
3. Choose the Right City and Hospital
Hospidio helps patients identify suitable hospitals based on several clinical factors, including:
- Experience of the hematology and transplant team
- Availability of dedicated bone marrow transplant units
- Infection-controlled isolation rooms
- Facilities for donor matching and stem cell collection
Choosing a center with strong transplant and hematology expertise is particularly important for patients being evaluated for advanced therapy.
4. Receive a Treatment Estimate and Timeline
After the clinical review, patients typically receive an estimated treatment plan and cost range.
This may include:
- Expected timeline for medical therapy cycles
- Stem cell transplant pathway (if applicable)
- Duration of hospital stay and follow-up monitoring
This step helps patients plan finances, accommodation, and travel schedules.
5. Obtain a Visa Letter and Prepare Travel
Once the treatment plan is confirmed, the hospital provides an official medical visa invitation letter.
Patients can then apply for:
- A Medical Visa for the patient
- A Medical Attendant Visa for a caregiver
Hospidio coordinators can also help arrange medical visa, travel planning, airport pickup, and accommodation near the hospital.
6. Arrive in India for Screening
After arrival, doctors usually perform baseline evaluations to confirm the treatment strategy. This step ensures that treatment decisions are based on the most accurate and current medical information.
7. Start Treatment and Plan Follow-Up
Once the evaluation is complete, the treating team begins the recommended therapy. Depending on the patient’s treatment plan, follow-up care may include:
- Continued treatment cycles in India
- Short-term stay for monitoring
- Teleconsultation follow-ups after returning home
Through coordinated care and specialist guidance, Hospidio helps international patients navigate each stage of the treatment journey from initial report review to recovery planning and follow-ups.
Top Hospitals for Bone Marrow Transplant in India
Planning MDS Treatment Abroad? We’re Here to Help.
Choosing where to receive treatment for Myelodysplastic Syndrome is an important decision. India offers advanced hematology care, experienced transplant teams, and significantly lower treatment costs compared to many Western countries.
Through Hospidio, international patients receive support at every step, including:
- Hospital and doctor selection
- Medical visa guidance
- Accommodation near treatment centers
- Airport transfers and local support
- Follow-up care coordination
Reach out to Hospidio to start planning your treatment journey in India with confidence.
Recent Blogs
Baani Singh is a Trainee Intern specializing in Content and Brand Management at HOSPIDIO. With a keen interest in healthcare communication, she contributes to creating informative and engaging content that bridges the gap between medical services and patients seeking treatment abroad. Her work supports HOSPIDIO's mission to provide accessible and transparent medical travel solutions.
Dr. Akash Khandelwal is a consultant hematologist with clinical expertise in hematologic malignancies, bone marrow transplantation, and advanced cellular therapies, including CAR T-cell therapy. He is actively involved in the management of complex blood cancers and immune disorders, with a strong focus on evidence-based treatment, patient safety, and long-term outcomes. Dr. Khandelwal works closely with multidisciplinary teams to deliver standardized, guideline-driven care for both domestic and international patients, combining clinical precision with a patient-centered approach.